Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
35.57
-0.25 (-0.70%)
At close: Mar 20, 2026, 4:00 PM EDT
36.00
+0.43 (1.21%)
After-hours: Mar 20, 2026, 6:49 PM EDT
Crinetics Pharmaceuticals Employees
Crinetics Pharmaceuticals had 594 employees as of December 31, 2025. The number of employees increased by 157 or 35.93% compared to the previous year.
Employees
594
Change (1Y)
157
Growth (1Y)
35.93%
Revenue / Employee
$12,956
Profits / Employee
-$783,362
Market Cap
3.72B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 594 | 157 | 35.93% | 594 | 0 |
| Dec 31, 2024 | 437 | 147 | 50.69% | 437 | 0 |
| Dec 31, 2023 | 290 | 80 | 38.10% | 290 | 0 |
| Dec 31, 2022 | 210 | 67 | 46.85% | 210 | 0 |
| Dec 31, 2021 | 143 | 50 | 53.76% | 143 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| ACADIA Pharmaceuticals | 798 |
| Corcept Therapeutics | 730 |
| ADMA Biologics | 647 |
| Structure Therapeutics | 220 |
| Centessa Pharmaceuticals | 114 |
| Spyre Therapeutics | 102 |
| NewAmsterdam Pharma Company | 100 |
CRNX News
- 23 days ago - Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March - GlobeNewsWire
- 7 weeks ago - Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewsWire
- 2 months ago - Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) - GlobeNewsWire
- 2 months ago - Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia - GlobeNewsWire